Literature DB >> 29280362

Overview of the improvement of the ring-stage survival assay-a novel phenotypic assay for the detection of artemisinin-resistant Plasmodium falciparum.

Jie Zhang1, Guo-Hua Feng2, Chun-Yan Zou3, Pin-Can Su4, Huai-E Liu1,5, Zhao-Qing Yang6.   

Abstract

Artemisinin resistance in Plasmodium falciparum threatens the remarkable efficacy of artemisinin-based combination therapies worldwide. Thus, greater insight into the resistance mechanism using monitoring tools is essential. The ring-stage survival assay is used for phenotyping artemisinin-resistance or decreased artemisinin sensitivity. Here, we review the progress of this measurement assay and explore its limitations and potential applications.

Entities:  

Keywords:  Application; Artemisinin; Improvement; Malaria; Resistant phenotype; Ring-stage survival assay

Mesh:

Substances:

Year:  2017        PMID: 29280362      PMCID: PMC5767555          DOI: 10.24272/j.issn.2095-8137.2017.075

Source DB:  PubMed          Journal:  Zool Res        ISSN: 2095-8137


INTRODUCTION

Malaria, which is mainly caused by Plasmodium falciparum, is a long-term worldwide public health problem. An estimated 216 million new cases occurred globally in 2016, resulting in 445 000 deaths (WHO, 2017). Despite significant progress in reducing morbidity and mortality rates in many areas of endemicity, drug resistance has become a challenging issue. Since P. falciparum developed resistance to chloroquine and sulfadoxine-pyrimethamine, malaria has spread rampantly throughout Asia and Africa over the last several decades (Snow et al., 2001; Trape et al., 1998), posing serious difficulties for its control and elimination. Originally discovered in China, artemisinin (ART) and its derivatives, including dihydroartemisinin (DHA), artemether, and artesunate, demonstrate high performance, low toxicity, and limited cross-resistance with other antimalarial drugs (Li et al., 1979; Miller & Su, 2011). ART is at the frontline for the treatment and possible cure of malaria (Fairhurst, 2015); however, along with its global application, resistance to ART has developed and increased in many regions. Since its first detection in 2008 (Noedl et al., 2008) and 2009 (Dondorp et al., 2009) in western Cambodia, ART resistance has appeared successively in other countries of the Greater Mekong Subregion, manifesting with a reduced parasite clearance rate or prolonged in vivo parasite clearance time following treatment with ART-based combination therapies (ACTs) (Amaratunga et al., 2012; Ashley et al., 2014; Hien et al., 2012; Huang et al., 2015; Kyaw et al., 2013; Phyo et al., 2012). For many decades, Southeast Asia (SEA) has been an epicenter for the evolution of drug-resistant falciparum malaria, and the emergence of ART resistance in SEA is of great concern for the global control of falciparum malaria (Fairhurst, 2015).

RING-STAGE SURVIVAL ASSAY

Hidden within ART-resistant parasites is the ability to remain dormant in the ring stage after exposure to ART, as well as recovery at a rapid rate, resulting in numerous parasites enduring DHA-exposed dormancy (Codd et al., 2011; Teuscher et al., 2010). Due to these special characteristics, despite substantial reductions in the clinical response to ART observed in falciparum malaria, in vitro concentrations resulting in 50% growth inhibition in a conventional 48 h exposure assay were relatively low and did not contribute to slow parasite clearance or ACT failure (Dondorp et al., 2009; Saralamba et al., 2011; Woodrow & White, 2017). It is, therefore, necessary to implement rapid and exact monitoring to halt the further spread of ART-resistance. Hence, the ring-stage survival assay (RSA) was recently established as a new protocol in the surveillance of ART resistance, and can distinguish culture-adapted isolates with fast clearance or slow-clearing rates that can survive pharmacologically relevant doses of ART (Dondorp et al., 2009; Witkowski et al., 2013a). Previous therapeutic efficacy studies have demonstrated a clear correlation between RSA in vitro and day 3 parasitemia positivity as well as mutations in the Kelch domain gene (K13) associated with resistance (Woodrow & White, 2017; Ariey et al., 2014; Wang et al., 2015; Zhang et al., 2016). Current data have shown RSA to be an important assay for ART resistance in vitro. In RSA, young ring-stage parasite cultures (0-3 h), tightly synchronized by 5% sorbitol, are exposed to 700 nmol/L DHA or 0.1% dimethyl sulfoxide (DMSO) as controls for 6 h, then cultivated for 66 h after twice or thrice drug washing. At the end of the assay, survival rates of these isolates are calculated as the ratio under the microscope of viable parasites surviving DHA-induced incubation relative to initial conditions (rsa-evaluate-vitro-and-ex-vivo-susceptibility" target="_blank">http://www.wwarn.org/tools-resources/procedures/ring-stage-survival-assays-rsa-evaluate-vitro-and-ex-vivo-susceptibility). In general, a ≥1% survival rate is defined as an ART-resistant strain (Figure 1). Schematic representation of the ring-stage survival assay in vitro This method can decrease interference caused by the internal variables of the host, such as organism immunity level, allosteric effects of hemoglobin, and capability to metabolize drugs (Amaratunga et al., 2012; Witkowski et al., 2013a). RSA in vitro is proposed to give phenotypic information, thus enabling screening for reduced susceptibility to ART in prolonged clearance parasites (Witkowski et al., 2013b).

IMPROVED METHODS FOR RSA

While feasible and efficient for the surveillance of ART resistance, the RSA tool has several limitations, including sophisticated Percoll gradient centrifugation, biased assessment of the degree of sorbitol synchronization treatment, and exacting requirements for counting viable parasites (Witkowski et al., 2013a). In Whitney A. Kite's laboratory, two alternative RSA methods have been developed; that is, filtration ring-stage survival assay and sorbitol-only ring-stage survival assay. The first is essentially a filtration process in which the 0-3 h fresh post-invasion rings are obtained after filtering out the merozoites from mature forms. The latter assay performs a repeated step of high synchronization prior to measurement, with the remaining late-stage schizonts typically removed, except for the early rings. Compared with the standard RSA protocol, these modifications have shown a marked increase in phase-specificity as well as less time in culture, fewer lab resources, and lower volume of isolates (Kite et al., 2016). In addition, to limit the inherent variability of microscopic examination, Amaratunga et al. (2014) developed a quick and simple bi-color flow cytometric assay -RSA-2FACS and MitoTracker deep red FM (MTDR) -to accurately quantify observations of viable parasites applied to the RSA. In their study, mitochondrial DNA is readily dyed using the Mito Tracker deep red FM method, allowing for the selection of viable parasites from pyknotic strains (Amaratunga et al., 2014). In addition, Dogovski et al. (2015) suggested direct assessment of the drug-induced growth effects in western Cambodian parasites. For this, the RNA-binding dye SYTO-61, which can distinguish isolates in different stages, was used as a fluorescent marker to determine whether parasites that survived DHA exposure exhibited growth retardation. By comparison with no-drug controls, the decreased SYTO-61 signal in the drug-treated samples exhibited an absolute increase in the number of viable parasites (Dogovski et al., 2015).

PROSPECT AND APPLICATION OF RSA

The traditional RSA approach was first carried out by Witkowski and colleagues based on sensitivity to DHA exposure at different stages. Their results demonstrated that median ring-stage survival of laboratory lines collected in western Cambodia with slow-clearing infection was 47-fold higher than those with normal ART sensitivity in RSA0-3h (0.23 and 10.88%, respectively), whereas no significant differences were observed in RSA9-12h or trophozoite-stage survival assay (TSA18-21h) rates (Witkowski et al., 2013a). In contrast, Cui et al. (2012) demonstrated that the ART resistance phenotype was associated with the dormancy mechanism not only at the development of the ring stage, but also in trophozoites and schizonts (Cui et al., 2012). Thus, the different consequences involved in the characteristics of this phenotype require additional empirical evidence. Cooper et al. (2015) documented that DHA susceptibility using the standard RSA based on the IC50 value for ART failed to clarify resistance in P. falciparum parasites from Kampala, Uganda, with the parasitemia of almost all isolates dropping to a much lower level (≤0.025%) after the 72-h assay, revealing no sign of ART resistance. Susceptibility to ART in Cameroonian isolates was also identified using ex-vivo RSA, with the DHA-treated cultures showing almost no healthy-appearing parasites (median survival rate=0.49%, IQR=0% to 1.3%) (Menard et al., 2016). However, reduced ART drug in-vitro sensitivity of parasites from the China-Myanmar border was reported after assessment of early ring-stage survival by comparing 34 clinical isolates with the 3D7 reference standard strain (Zhang et al., 2016). The RSA0-3h assay was recently developed to test ART resistance for P. falciparum isolates. This assay has been subsequently improved in terms of simplicity and practicality. Thus, the growing availability of RSA will increase the convenience and ease of investigating ART responses in laboratory testing.
  26 in total

Review 1.  The past, present and future of childhood malaria mortality in Africa.

Authors:  R W Snow; J F Trape; K Marsh
Journal:  Trends Parasitol       Date:  2001-12

Review 2.  Understanding artemisinin-resistant malaria: what a difference a year makes.

Authors:  Rick M Fairhurst
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

3.  Evidence of artemisinin-resistant malaria in western Cambodia.

Authors:  Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda
Journal:  N Engl J Med       Date:  2008-12-08       Impact factor: 91.245

4.  Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays.

Authors:  Roland A Cooper; Melissa D Conrad; Quentin D Watson; Stephanie J Huezo; Harriet Ninsiima; Patrick Tumwebaze; Samuel L Nsobya; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

5.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria.

Authors:  Frédéric Ariey; Benoit Witkowski; Chanaki Amaratunga; Johann Beghain; Anne-Claire Langlois; Nimol Khim; Saorin Kim; Valentine Duru; Christiane Bouchier; Laurence Ma; Pharath Lim; Rithea Leang; Socheat Duong; Sokunthea Sreng; Seila Suon; Char Meng Chuor; Denis Mey Bout; Sandie Ménard; William O Rogers; Blaise Genton; Thierry Fandeur; Olivo Miotto; Pascal Ringwald; Jacques Le Bras; Antoine Berry; Jean-Christophe Barale; Rick M Fairhurst; Françoise Benoit-Vical; Odile Mercereau-Puijalon; Didier Ménard
Journal:  Nature       Date:  2013-12-18       Impact factor: 49.962

6.  Artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Arjen M Dondorp; François Nosten; Poravuth Yi; Debashish Das; Aung Phae Phyo; Joel Tarning; Khin Maung Lwin; Frederic Ariey; Warunee Hanpithakpong; Sue J Lee; Pascal Ringwald; Kamolrat Silamut; Mallika Imwong; Kesinee Chotivanich; Pharath Lim; Trent Herdman; Sen Sam An; Shunmay Yeung; Pratap Singhasivanon; Nicholas P J Day; Niklas Lindegardh; Duong Socheat; Nicholas J White
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

7.  Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.

Authors:  Chanaki Amaratunga; Sokunthea Sreng; Seila Suon; Erika S Phelps; Kasia Stepniewska; Pharath Lim; Chongjun Zhou; Sivanna Mao; Jennifer M Anderson; Niklas Lindegardh; Hongying Jiang; Jianping Song; Xin-zhuan Su; Nicholas J White; Arjen M Dondorp; Tim J C Anderson; Michael P Fay; Jianbing Mu; Socheat Duong; Rick M Fairhurst
Journal:  Lancet Infect Dis       Date:  2012-08-30       Impact factor: 25.071

8.  Spread of artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Elizabeth A Ashley; Mehul Dhorda; Rick M Fairhurst; Chanaki Amaratunga; Parath Lim; Seila Suon; Sokunthea Sreng; Jennifer M Anderson; Sivanna Mao; Baramey Sam; Chantha Sopha; Char Meng Chuor; Chea Nguon; Siv Sovannaroth; Sasithon Pukrittayakamee; Podjanee Jittamala; Kesinee Chotivanich; Kitipumi Chutasmit; Chaiyaporn Suchatsoonthorn; Ratchadaporn Runcharoen; Tran Tinh Hien; Nguyen Thanh Thuy-Nhien; Ngo Viet Thanh; Nguyen Hoan Phu; Ye Htut; Kay-Thwe Han; Kyin Hla Aye; Olugbenga A Mokuolu; Rasaq R Olaosebikan; Olaleke O Folaranmi; Mayfong Mayxay; Maniphone Khanthavong; Bouasy Hongvanthong; Paul N Newton; Marie A Onyamboko; Caterina I Fanello; Antoinette K Tshefu; Neelima Mishra; Neena Valecha; Aung Pyae Phyo; Francois Nosten; Poravuth Yi; Rupam Tripura; Steffen Borrmann; Mahfudh Bashraheil; Judy Peshu; M Abul Faiz; Aniruddha Ghose; M Amir Hossain; Rasheda Samad; M Ridwanur Rahman; M Mahtabuddin Hasan; Akhterul Islam; Olivo Miotto; Roberto Amato; Bronwyn MacInnis; Jim Stalker; Dominic P Kwiatkowski; Zbynek Bozdech; Atthanee Jeeyapant; Phaik Yeong Cheah; Tharisara Sakulthaew; Jeremy Chalk; Benjamas Intharabut; Kamolrat Silamut; Sue J Lee; Benchawan Vihokhern; Chanon Kunasol; Mallika Imwong; Joel Tarning; Walter J Taylor; Shunmay Yeung; Charles J Woodrow; Jennifer A Flegg; Debashish Das; Jeffery Smith; Meera Venkatesan; Christopher V Plowe; Kasia Stepniewska; Philippe J Guerin; Arjen M Dondorp; Nicholas P Day; Nicholas J White
Journal:  N Engl J Med       Date:  2014-07-31       Impact factor: 91.245

9.  Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates.

Authors:  Sandie Menard; Joëlle Njila Tchoufack; Christelle Ngou Maffo; Sandrine E Nsango; Xavier Iriart; Luc Abate; Majoline Tchioffo Tsapi; Parfait H Awono-Ambéné; Francis A Abega Mekongo; Isabelle Morlais; Antoine Berry
Journal:  Malar J       Date:  2016-11-26       Impact factor: 2.979

10.  Alternative methods for the Plasmodium falciparum artemisinin ring-stage survival assay with increased simplicity and parasite stage-specificity.

Authors:  Whitney A Kite; Viviana A Melendez-Muniz; Roberto R Moraes Barros; Thomas E Wellems; Juliana M Sá
Journal:  Malar J       Date:  2016-02-17       Impact factor: 2.979

View more
  4 in total

1.  Rapid and quantitative antimalarial drug efficacy testing via the magneto-optical detection of hemozoin.

Authors:  Petra Molnár; Ágnes Orbán; Richard Izrael; Réka Babai; Lívia Marton; Ádám Butykai; Stephan Karl; Beáta G Vértessy; István Kézsmárki
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

2.  In vitro susceptibility of Plasmodium falciparum isolates from the China-Myanmar border area to artemisinins and correlation with K13 mutations.

Authors:  Jie Zhang; Na Li; Faiza A Siddiqui; Shiling Xu; Jinting Geng; Jiaqi Zhang; Xi He; Luyi Zhao; Liang Pi; Yanmei Zhang; Cuiying Li; Xi Chen; Yanrui Wu; Jun Miao; Yaming Cao; Liwang Cui; Zhaoqing Yang
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-04-10       Impact factor: 4.077

3.  Ex vivo susceptibilities of Plasmodium vivax isolates from the China-Myanmar border to antimalarial drugs and association with polymorphisms in Pvmdr1 and Pvcrt-o genes.

Authors:  Jiangyan Li; Jie Zhang; Qian Li; Yue Hu; Yonghua Ruan; Zhiyong Tao; Hui Xia; Jichen Qiao; Lingwen Meng; Weilin Zeng; Cuiying Li; Xi He; Luyi Zhao; Faiza A Siddiqui; Jun Miao; Zhaoqing Yang; Qiang Fang; Liwang Cui
Journal:  PLoS Negl Trop Dis       Date:  2020-06-12

4.  Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar.

Authors:  Yanrui Wu; Myat Thut Soe; Pyae Linn Aung; Luyi Zhao; Weilin Zeng; Lynette Menezes; Zhaoqing Yang; Myat Phone Kyaw; Liwang Cui
Journal:  Malar J       Date:  2020-08-27       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.